Skip to Content
Biotechnology and health

Robot-assisted high-precision surgery has passed its first test in humans

February 11, 2020
Surgeons operating on someone's arm using a robot
Surgeons operating on someone's arm using a robotMicrosure

A trial of a new high-precision surgical robot used to operate on women with breast cancer found the system is safe. 

Super-small: It’s the first human trial of a robot for “supermicrosurgery,” a term referring to surgery on vessels that range from 0.3 to 0.8 millimeters. It’s a form of surgery that only a small number of surgeons worldwide can perform.

The trial: Researchers from Maastricht University assembled a group of 20 women with lymphedema, a condition related to breast cancer in which excess fluid collects in tissues, causing swelling. They were all scheduled to receive surgery to relieve their symptoms by connecting lymph vessels to nearby veins, thus bypassing the affected area. They were split into two groups: one to receive solely manual surgery, the other to be operated on by surgeons using a robotic system called MUSA, manufactured by a Dutch company called Microsure.

How the robot works: The system is activated by foot pedals, and a surgeon controls the high-precision surgical instruments using forceps-like joysticks, mounted to the operating table. This setup basically cancels out small tremors in the surgeons’ hands and scales down their hand movements into more refined and subtle versions. For example, if the surgeon moves one of the joysticks by one centimeter, the robot arm moves a tenth of a millimeter. 

Results: The group under robotic surgery healed slightly more quickly when researchers checked back on them, but beyond that there were few differences between the two. However, the point of the trial was to prove that the robotic system is safe and feasible, rather than to demonstrate superiority.

Why it matters: Robot surgery is nothing new. The Da Vinci system, the best-selling surgery robot on the market, was approved by the FDA two decades ago. It can operate with a degree of precision down to 1 millimeter, but it has not been found to be any better than traditional surgery, and with its $2 million price tag—plus maintenance fees—it is more expensive. Very high-precision surgery is a niche where robotic gadgets could potentially prove their worth, essentially by turning decent surgeons into world-class ones. However, they’ll need to be tested by many more surgeons on a lot more patients for us to be sure.

Deep Dive

Biotechnology and health

FDA advisors just said no to the use of MDMA as a therapy

The studies demonstrating MDMA’s efficacy against PTSD left experts with too many questions to greenlight the treatment.

Biotech companies are trying to make milk without cows

The bird flu crisis on dairy farms could boost interest in milk protein manufactured in microorganisms and plants. 

What’s next for MDMA

The FDA is poised to approve the notorious party drug as a therapy. Here’s what it means, and where similar drugs stand in the US. 

My biotech plants are dead

Two ‘Firefly petunias’ perished in a shipping misadventure, but other customers have had better luck.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.